| Patent application number | Description | Published |
|---|
| 20090053218 | FcGammaRIIB Specific Antibodies and Methods of Use Thereof - The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The present invention also encompasses the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The present invention also encompasses the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, in combination with other cancer therapies. The present invention provides pharmaceutical compositions comprising an anti-FcγRIIB antibody or an antigen-binding fragment thereof, in amounts effective to prevent, treat, manage, or ameliorate a cancer, such as a B-cell malignancy, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention further provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention with a vaccine composition. | 02-26-2009 |
| 20090074771 | FcGammaRIIB Specific Antibodies and Methods of Use Thereof - The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, more particularly the extracellular domain of FcγRIIB with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA, and block the Fc binding site of FcγRIIB. The present invention also encompasses the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The present invention also encompasses the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, in combination with other cancer therapies. The present invention provides pharmaceutical compositions comprising an anti-FcγRIIB antibody or an antigen-binding fragment thereof, in amounts effective to prevent, treat, manage, or ameliorate a cancer, such as a B-cell malignancy, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention further provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention with a vaccine composition. The invention further provides methods of treating cancer and/or regulating immune complex-mediated cell activation by administering the antibodies of the invention to enhance an immune response. The invention also provides methods of breaking tolerance to an antigen by administering an antigen-antibody complex and an antibody of the invention. | 03-19-2009 |
| 20090076251 | FcGammaRIIB Specific Antibodies and Methods of Use Thereof - The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, more particularly the extracellular domain of FcγRIIB with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA, and block the Fc binding site of FcγRIIB. The present invention also encompasses the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The present invention also encompasses the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, in combination with other cancer therapies. The present invention provides pharmaceutical compositions comprising an anti-FcγRIIB antibody or an antigen-binding fragment thereof, in amounts effective to prevent, treat, manage, or ameliorate a cancer, such as a B-cell malignancy, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention further provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention with a vaccine composition. The invention further provides methods of treating cancer and/or regulating immune complex-mediated cell activation by administering the antibodies of the invention to enhance an immune response. The invention also provides methods of breaking tolerance to an antigen by administering an antigen-antibody complex and an antibody of the invention. | 03-19-2009 |
| 20110097323 | Her2/neu-Specific Antibodies and Methods of Using Same - This invention relates to antibodies that specifically bind HER2/neu, and particularly chimeric 4D5 antibodies to HER2/neu, which have reduced glycosylation as compared to known 4D5 antibodies. The invention also relates to methods of using the 4D5 antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease. | 04-28-2011 |
| 20120034221 | T-Cell Receptor Antibodies And Methods of Use Thereof - The present invention is directed to the production and use of monoclonal antibodies, or antigen binding fragments thereof, that specifically bind the T cell antigen receptor (TCR) and their use for immunomodulation. In preferred embodiments, the antibody or antigen binding fragment of the invention specifically binds the constant region of the α chain of the TCR, or otherwise specifically binds the α chain regardless of TCR clonal origin (i.e., is pan specific for TCR). The antibodies of the invention may be used, for example, in immunosuppressive therapies for transplant maintenance and the treatment of autoimmune diseases, and/or as targeting molecules for use in the treatment of T-cell malignancies. | 02-09-2012 |
| Patent application number | Description | Published |
|---|
| 20100269976 | PROCESS AND PLANT FOR BUILDING TYRES FOR VEHICLE WHEELS - A process for building tyres for vehicle wheels wherein each tyre includes a carcass structure and a crown structure, the crown structure including a belt structure including a first radially inner belt layer and at least one second belt layer radially external to the first belt layer, the process including the steps of: a) placing an annular assembly including a first radially inner belt layer and at least one second radially outer belt layer on at least one auxiliary turning up drum; b) defining at least one pair of folding lines in axially opposite positions of the annular assembly by respective abutment devices radially external to the auxiliary turning up drum; c) adjusting the axial position of the folding lines relative to a centre line plane of the auxiliary turning up drum; and d) turning up, at the folding lines, at least a part of end portions of the first belt layer axially protruding relative to the at least one second belt layer on the at least one second belt layer of the annular assembly. | 10-28-2010 |
| 20100276067 | PROCESS AND PLANT FOR BUILDING TYRES FOR VEHICLE WHEELS - A process for building tyres for vehicle wheels includes the steps of: i) building a carcass structure of a green tyre in at least one carcass structure building line, the carcass structure including at least one carcass ply and a pair of annular anchoring structures; ii) building a crown structure of a green tyre in at least one crown structure building line, the crown structure including a belt structure and a tread band; wherein step ii) of building the crown structure includes at least one step iii) of building the belt structure which in turn includes the steps of: a) building on at least one first building drum, an annular assembly including a first radially inner belt layer and at least a second belt layer radially external to the first belt layer; b) transferring the annular assembly on at least one auxiliary drum; c) turning up axially opposite end portions of the fast radially inner belt layer so as to obtain at least a partial overlapping of the end portions of the first belt layer on the at least one second radially outer belt layer; and d) transferring said annular assembly from the at least one auxiliary drum on at least one second building drum. | 11-04-2010 |
| 20100307662 | PROCESS AND PLANT FOR PRODUCING TYRES FOR VEHICLE WHEELS - A plant and a process for producing tyres for vehicle wheels, includes the steps of: a) building a carcass structure of a green tyre on a first forming drum in at least one carcass structure building line, the carcass structure including at least one carcass ply and a pair of annular anchoring structures; b) building a crown structure of a green tyre on at least one second forming drum in at least one crown structure building line, the crown structure including at least one belt structure and a tread band; c) toroidally shaping the carcass structure assembling it to the crown structure in at least one assembling and shaping work station for the tyre being processed, the assembling and shaping work station being synchronised with the carcass structure building line and with the crown structure building line; wherein each carcass structure is associated with the respective first forming drum whereon it is built up to the end of step c) of shaping and assembling the tyre being processed; and d) moulding and vulcanizing the green shaped tyre in at least one tyre moulding and vulcanizing line separate from said assembling and shaping work station. | 12-09-2010 |
| 20110247741 | PROCESS FOR MANUFACTURING A TYRE, AND TYRE OBTAINED THEREFROM - During building of a carcass structure, a liner is applied around an outer surface of a primary drum by: circumferentially winding at least one pair of sheets of elastomeric material around an outer surface of the primary drum, which sheets are axially spaced apart from each other so as to form respective axially external portions of the liner; laying at least one continuous elongated element of elastomeric material in the form of a plurality of mutually approached coils around the outer surface of the primary drum in order to form a central portion of the liner having axially external edges that are each associated with an axially internal edge of one of said axially external portions of the liner. | 10-13-2011 |
